Clinical Trial Update: Rifaximin's Effect on Covert Hepatic Encephalopathy With SIBO and Gastrointestinal Dysmotility [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating rifaximin for covert hepatic encephalopathy with SIBO and GI dysmotility was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cirrhosis
• Gastrointestinal Motility Disorder
• Minimal Hepatic Encephalopathy
• Small Intestinal Bacterial Overgrowth

Drugs mentioned

• Rifaximin (rifaximin)

Snippet

Sponsor: MetroHealth Medical Center | Conditions: Cirrhosis, Liver, Minimal Hepatic Encephalopathy | Phase 3 | Status: WITHDRAWN